Stock DHT.UN DRI HEALTHCARE TRUST
Add to a list
To use this feature you must be a member
Log inSign up

Financials DRI Healthcare Trust

Equities

DHT.UN

CA23344H1091

Pharmaceuticals

Delayed Toronto S.E.
Other stock markets
 10:20:15 09/05/2024 pm IST 		5-day change 1st Jan Change
16.02 CAD -0.87% Intraday chart for DRI Healthcare Trust -0.80% +28.37%
07/05 Transcript : DRI Healthcare Trust, Q1 2024 Earnings Call, May 07, 2024
06/05 DRI Healthcare Trust Brief: Q1 Total Income of US$42.1 million; Comprehensive Loss of US$5.0 million; Adjusted Cash Earnings per Unit of US$0.47 (basic and diluted); Net Loss per Unit of US$0.11 (basic and diluted) MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 214.1 225 530.5 663.8 - -
Enterprise Value (EV) 1 196.3 433.3 530.5 804.7 758.7 612.3
P/E ratio 8.61 x 19.4 x 4.55 x - - 5.1 x
Yield 7.24% 8% - 3.27% 3.56% 4.26%
Capitalization / Revenue 2.62 x 2.42 x 3.19 x 4.01 x 3.97 x 3.52 x
EV / Revenue 2.4 x 4.66 x 3.19 x 4.87 x 4.53 x 3.25 x
EV / EBITDA 1.95 x 5.26 x 4.69 x 5.23 x 5.35 x 3.87 x
EV / FCF 2.14 x -2.21 x - 6.97 x 7.42 x 6.5 x
FCF Yield 46.8% -45.3% - 14.4% 13.5% 15.4%
Price to Book 0.55 x 0.59 x - 1.14 x 1.05 x 0.88 x
Nbr of stocks (in thousands) 40,107 38,666 56,358 56,368 - -
Reference price 2 5.339 5.819 9.414 11.78 11.78 11.78
Announcement Date 07/03/22 01/03/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 81.76 93.03 166.3 165.3 167.4 188.5
EBITDA 1 - 100.6 82.44 113.2 153.8 141.7 158.1
EBIT 1 - 58.79 23.17 26.13 61 - -
Operating Margin - 71.9% 24.91% 15.72% 36.89% - -
Earnings before Tax (EBT) 1 - - - 92.3 28 - -
Net income 1 -0.00036 21.56 11.6 92.3 29.7 62.24 48.45
Net margin - 26.37% 12.47% 55.51% 17.96% 37.18% 25.71%
EPS 2 - 0.6200 0.3000 2.070 - - 2.310
Free Cash Flow 1 - 91.86 -196.2 - 115.5 102.3 94.2
FCF margin - 112.35% -210.89% - 69.87% 61.09% 49.98%
FCF Conversion (EBITDA) - 91.29% - - 75.12% 72.15% 59.6%
FCF Conversion (Net income) - 426.03% - - 388.97% 164.3% 194.43%
Dividend per Share 2 - 0.3867 0.4655 - 0.3854 0.4198 0.5019
Announcement Date 10/02/21 07/03/22 01/03/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 22.86 22.21 22.62 21.3 26.47 22.64 28.24 28.06 34.14 75.84 42.07 39.44 42.15 41.91 37.57
EBITDA 1 12.41 31.97 17.81 21.44 15.81 27.37 21.43 25.07 20.25 46.45 55.11 32.73 32.11 38.07 33.01
EBIT 1.288 19.06 5.036 8.022 1.822 - 2.266 5.471 - - - - - - -
Operating Margin 5.63% 85.78% 22.26% 37.67% 6.88% - 8.03% 19.5% - - - - - - -
Earnings before Tax (EBT) - - - - - - - 75.03 - 22.18 - - - - -
Net income 1 - 3.362 - 3.097 7.614 -4.807 -1.123 75.03 -3.781 22.18 -6.197 1.6 11.4 10.3 12.7
Net margin - 15.13% - 14.54% 28.76% -21.23% -3.98% 267.42% -11.07% 29.24% -14.73% 4.06% 27.05% 24.57% 33.8%
EPS 2 0.1900 0.0800 0.1500 0.0800 0.2000 -0.1300 -0.0300 2.000 -0.0800 0.3900 -0.1100 - 0.0200 0.0100 -0.0400
Dividend per Share 2 0.0375 0.2950 0.0750 0.0750 0.0750 - 0.5405 0.0750 - - 0.1761 0.0850 0.0850 0.2352 -
Announcement Date 08/11/21 07/03/22 10/05/22 03/08/22 07/11/22 01/03/23 11/05/23 14/08/23 13/11/23 28/02/24 06/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 208 - 141 94.9 -
Net Cash position 1 - 17.8 - - - - 51.5
Leverage (Debt/EBITDA) - - 2.527 x - 0.9163 x 0.6693 x -
Free Cash Flow 1 - 91.9 -196 - 116 102 94.2
ROE (net income / shareholders' equity) - 33.8% 19.2% - 21.2% 22.3% 21.4%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 9.700 9.850 - 10.40 11.30 13.40
Cash Flow per Share 2 - 2.650 2.010 - 3.420 - -
Capex 1 - - 274 - 146 - -
Capex / Sales - - 294.16% - 88.56% - -
Announcement Date 10/02/21 07/03/22 01/03/23 28/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for DRI Healthcare Trust

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
11.78 USD
Average target price
14.94 USD
Spread / Average Target
+26.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DRI HEALTHCARE TRUST Stock DRI Healthcare Trust
+28.37% 664M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.87% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.55% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.17% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.63% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.34% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+8.49% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DHT.UN Stock
  4. Financials DRI Healthcare Trust
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW